🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million instances annually. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the face of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Secure Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone signifies a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Global Access

As per findings detailed in a major medical journal, the new drug eradicated the vast majority of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves two antibiotics. The research included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced positive views. Access to a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.